Skip to main content
OpenTrials
Completed

NCT Number: NCT02423707

Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy

Allergen-specific immunotherapy (ASIT) is commonly used to treat patients with allergic rhino-conjunctivitis and asthma, and it is the only proven treatment that affects the long-term development of allergic rhinitis and asthma. The current treatment regime of ASIT requires numerous subcutaneous allergen injections and takes several years to complete. Hence, there is a need to develop more convenient protocols for induction of allergen tolerance.

Emerging evidence suggest that by targeting of antigen presenting cells within the lymph nodes the immunogenicity of the allergen can be enhanced and the number of injections can be reduced.

The purpose of this study is to evaluate whether intralymphatic administration of ASIT is a safe and effective treatment for patients with pollen-induced allergic rhinitis. The long term goal is to provide a base for a more efficient administration of ASIT, which will reduce both the dose necessary and the number of clinic visits associated with the conventional subcutaneous ASIT.

The investigators will make an attempt to reproduce the results of a recent human study of intralymphatic ASIT (clinicaltrials.gov; NCT00470457) in a Swedish clinical setting.

The first part of the study is completed and published (PMID: 23374268)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergic Rhinitis Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Nose Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis, Allergic

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Allergic Unit at the Department of Oto-Rhino-Laryngology at Skåne University Hospital Malmö

Malmö, 20502, Sweden

About this study

In the first part of the study safety and clinical efficacy of ALK Alutard Birch or 5-grass have been evaluated in a RCT with 50 patients. Active patients recieve 3 injections with 1000 SQ-U ALK Alutard or 5-grasses in a lymph node in the groin. Dose interval 4 weeks. This part of the study is completed and published (PMID: 23374268)

In the second part of the study 60 patients participates in a RCT with intralymphatic injections with both ALK Alutard Birch AND ALK Alutard 5-grasses. The injections are given intralymphatically with one allergen in each groin with 30 minutes observation between injections. Dose and dose interval are the same as in the first part of the study; the active group recieves 1000 SQ-U ALK Alutard Birch in right groin and 1000 SQ-U 5-grasses in left groin. The injections are given 3 times with 4 weeks interval. Enrollment and treatment is completed and the results will be evaluated in the autumn 2015.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-50,
  • Seasonal allergic symptoms for birch and/or grass verified by skin prick test,
  • Accepted informed consent

Exclusion criteria

  • Pregnancy or nursing
  • Autoimmune or collagen disease (known)
  • Cardiovascular disease
  • Perennial pulmonary disease
  • Hepatic disease
  • Renal disease
  • Cancer
  • Any medication with a possible side-effect of interfering with the immune response
  • Previous immuno- or chemotherapy
  • Chronic diseases
  • Other upper airway disease (non-allergic sinusitis, nasal polyps, chronic obstructive and restrictive lung disease)
  • Disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension and treatment with β-blockers)
  • Major metabolic disease
  • Known or suspected allergy to the study product
  • Alcohol or drug abuse
  • Mental incapability of coping with the study
  • Withdrawal of informed consent

Treatment and study plan

ALK Alutard Birch and/or 5-grasses

Drug

3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.

The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use.

Other names: ALK Alutard Betula Verrucosa and ALK Alutard 5-grasses

ALK Diluent

Drug

This placebo group will receive 3 injections of 0.3% human albumin instead of active substance

Other names: Human albumin

Primary outcomes

  1. Change in subjective allergic symptoms following nasal allergen provocation

    Time frame: Before treatment, an average of 4 weeks after completed treatment and 6-9 months after treatment.

    The study subjects will be intranasally challenged with allergen and symptom score questionnaires are filled out pre-provocation and 5, 10 and 30 min post-provocation.

Secondary outcomes

  1. Registration of adverse event

    Time frame: from the first injection to 30 days after the last injections has been given

  2. Effects on quality of life

    Time frame: During peak pollen season which will be up to 5 months (birch) and 6 months (grass) after completed treatment

    SNOT-22 questionnaire

  3. Effects on quality of life

    Time frame: During peak pollen season which will be up to 5 months (birch) and 6 months (grass) after completed treatment

    Juniper RQLQ questionnaires

  4. Change in medicine consumption during pollen season

    Time frame: 6-9 months after treatment.

    After the pollen season patients report to what extension they have been using medications; more, the same or less. The mediacations asked about are antihistamine tablets, antihistamine eye drops, nasal steroid, steroid tablets, b2-bronchodilator inhalation, leucotrien receptor antagonist, nasal or ocular sodium chromoglycates.

  5. Change in symptoms at pollen season

    Time frame: 6-9 months after treatment.

    After the pollen season at the 6-9 months follow up patients recall the pollen season and rates the improvement on an arbitrary scale ranging 0-10 with 0 as "no improvement at all" and 10 "total symptom relief".

  6. Short term improvement of skin reactivity

    Time frame: Before treatment, an average of 4 weeks after completed treatment and 6-9 months after treatment.

    Skin prick test

  7. S-IgE Birch

    Time frame: Before treatment, approximately 4 weeks after completed treatment and 6-9 months after treatment

  8. S-IgE Grass

    Time frame: Before treatment, approximately 4 weeks after completed treatment and 6-9 months after treatment

  9. S-IgG4 Grass

    Time frame: Before treatment, approximately 4 weeks after completed treatment and 6-9 months after treatment

  10. S-IgG4 Birch

    Time frame: Before treatment, approximately 4 weeks after completed treatment and 6-9 months after treatment

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Karolinska University Hospital
  • Skane University Hospital

Registry information

Official study title

Intralymphatic Allergen-specific Immunity as a New Administration Route for Treatment of Pollen-induced Allergic Diseases

Important dates

Study start
2010
Primary completion
2015
Study completion
2017
First posted
Apr 22, 2015
Registry last updated
Aug 20, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.